Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Praveen, Dhankhar"'
Autor:
Cesar Lopez-Vinueza, Juan Urrego-Reyes, Fredy R. S. Gutierrez, Victoria Wurcel, Shujing Zhang, Shan Jiang, Ruixuan Jiang, Angela Zambrano Harvey, Praveen Dhankhar, Baanie Sawhney, Gargi Baluni, Shrishti Jain, Debosmita Bhadra
Publikováno v:
Advances in Therapy. 40:2836-2854
Autor:
Danny C Hsu, Monika Achra, Praveen Dhankhar, Ralph P. Insinga, Herbert H. Loong, Sheenu Chandwani, Carlos K. H. Wong, Akanksha Rai, Seng Chuen Tan, Min Huang, James M. Pellissier, Linda Kam Suet Leung, Mary Y.K. Lee
Publikováno v:
PharmacoEconomics Open
Background Pembrolizumab, a monoclonal antibody against programmed death ligand 1 (PD-L1), is approved by several regulatory agencies for first-line treatment of metastatic non-small-cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS)
Publikováno v:
Journal of Medical Economics. 21:497-509
To compare 1-year costs and benefits of dapagliflozin (DAPA), a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, with those of other treatments for type 2 diabetes (T2D), such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), sulfonylureas (
Autor:
Praveen Dhankhar, Camilo J. Acosta, Chizoba Nwankwo, Elamin H. Elbasha, Michelle G. Goveia, Andreas Lauschke, M. Pillsbury
Publikováno v:
Value in Health. 18:358-367
ObjectiveTo assess the population-level impact and cost-effectiveness of hepatitis A vaccination programs in the United States.MethodsWe developed an age-structured population model of hepatitis A transmission dynamics to evaluate two policies of adm
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Elaine Chiquette,1 Elif A Oral,2 Abhimanyu Garg,3 David Araújo-Vilar,4 Praveen Dhankhar5 1Aegerion Pharmaceuticals, Cambridge, MA, USA; 2Brehm Center for Diabetes Research and Metabolism, Endocrinology and Diabetes Division, Department of Internal M
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 10
Background: Several long-term models have been developed to compare the economic impact of alternative anti-diabetic treatments. However short-term models, based on actual trial data, might give more accurate results and be preferable over long-term
Publikováno v:
Journal of Medical Economics. 16:1216-1227
To evaluate the impact of universal vaccination with a pentavalent rotavirus vaccine (RV5) on the healthcare burden and costs associated with rotavirus gastroenteritis (RGE) in Japan.The model included a hypothetical cohort of 1,091,156 children foll
Publikováno v:
Vaccine. 26:4251-4255
There is growing concern in the United States about the excessive use of rabies post exposure prophylaxis (PEP) treatment. In this paper we have estimated the cost effectiveness of rabies PEP treatment under various scenarios of rabies transmission.
Publikováno v:
Journal of Empirical Legal Studies. 4:163-183
We estimate the effect of medical malpractice on physician behavior and health outcomes of AMI patients. The National Practitioner Data Bank (NPDB) has been combined with the Nationwide Inpatient Sample (NIS). Frequency of paid claims and claims seve
Publikováno v:
Vaccine. 31(36)